Get the latest news, insights, and market updates on BBNX (Beta Bionics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Beta Bionics (BBNX) Valuation Concerns Mount as Forecast Revenue Growth Far Exceeds Market Average
Beta Bionics (BBNX) is forecast to grow revenue by 28.75% per year, significantly outpacing the US market’s 10.2% average annual growth. Despite robust top-line expansion, the company is currently unprofitable and expected to remain that way for at least the next three years, with no evidence of improvement in profits or margins recently. For investors, this sets up a clear trade-off: strong projected growth versus ongoing profitability challenges and elevated valuation concerns. See our full... Oct 30, 2025 - $BBNX
Beta Bionics (BBNX) Q3 2025 Earnings Transcript
Before we begin, we would like to remind you that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Please refer to the cautionary statements in the press release we issued earlier today as well as our SEC filings, including our Form 10-Q filed today for a detailed explanation of the inherent limitations of such forward-looking statements. Oct 29, 2025 - $BBNX
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Durable Medical Equipment (DME) channel Oct 28, 2025 - $BBNX
Beta Bionics, Inc. (BBNX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Beta Bionics, Inc. (BBNX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Oct 28, 2025 - $BBNX
Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook
Beta Bionics Inc. (NASDAQ:BBNX) is one of the best hot stocks to invest in. On October 1, Goldman Sachs upgraded Beta Bionics to Buy from Neutral with a price target of $26, which was upgraded from $18. Goldman Sachs’ analysis of the diabetes technology market shows sustained growth and profitability for Beta Bionics. Earlier in […] Oct 16, 2025 - $BBNX
Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company’s we Oct 9, 2025 - $BBNX
InspireMD Announces the Appointment of Dan Dearen to its Board of Directors
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value throu Sep 17, 2025 - $BBNX
Bain Capital-backed Heartflow eyes $1.32 billion valuation as medtech IPOs rebound
(Reuters) -Medical technology company Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its U.S. initial public offering, more than three years after its previous attempt to go public fell through. Mountain View, California-based Heartflow is seeking up to $212.5 million by offering 12.5 million shares priced between $15 and $17 apiece. Heartflow's listing also comes amid a nascent rebound in medical technology IPOs after a years-long downturn. Aug 1, 2025 - $BBNX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple